Impact of Sacubitril/Valsartan on Heart Failure Outcomes in Men and Women
Author Information
Author(s): Abumayyaleh Mohammad, Krack Carina, Demmer Jonathan, Pilsinger Christina, Schupp Tobias, Behnes Michael, Sattler Katherine, El-Battrawy Ibrahim, Hamdani Nazha, Akin Ibrahim
Primary Institution: University Medical Center Mannheim, Heidelberg University, Mannheim, Germany
Hypothesis
Does sacubitril/valsartan improve clinical outcomes differently in women and men with heart failure with reduced ejection fraction?
Conclusion
Women with heart failure treated with sacubitril/valsartan showed greater improvement in left ventricular ejection fraction compared to men, but clinical outcomes were similar across sexes.
Supporting Evidence
- Women showed a significant improvement in left ventricular ejection fraction compared to men.
- Mortality rates were similar between women and men at 12 months.
- Female sex was not a predictor for ventricular tachyarrhythmias or mortality.
Takeaway
This study found that women with heart failure improved more than men when treated with a specific heart medication, but both groups had similar health outcomes.
Methodology
The study analyzed data from patients treated with sacubitril/valsartan at University Hospital Mannheim from 2016 to 2020, comparing outcomes between women and men.
Potential Biases
Potential bias due to unknown confounders and retrospective nature of the study.
Limitations
The study is retrospective, single-center, with a limited follow-up period and a small number of patients.
Participant Demographics
50 women (20.3%) and 196 men (79.7%), median age of women was 71.5 years and men was 70 years.
Statistical Information
P-Value
p=0.009 for LVEF improvement in women vs. men
Confidence Interval
95%-CI 0.17–2.016 for ventricular tachyarrhythmias; 95%-CI 0.381–9.464 for mortality
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website